金河生物科技股份有限公司（以下简称"公司"）于2025年4月18日及2025 年5月6日分别召开了第六届董事会第二十四次会议和2025年第二次临时股东大 会，审议并通过了《关于变更公司注册资本及修订<公司章程>部分条款的议案》。 具 体 内 容 详 见 公 司 于 2025 年 4 月 19 日 、 2025 年 5 月 7 日 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的相关公告。 公司于2025年6月10日及2025年6月26日分别召开了第六届董事会第二十六 次会议和2025年第三次临时股东大会，审议并通过了《关于增加公司经营范围并 修改<公司章程>的议案》。具体内容详见公司于2025年6月11日、2025年6月27 日于巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 证券代码：002688 证券简称：金河生物 公告编号：2025-064 金河生物科技股份有限公司 关于完成工商变更登记的公告 公司于近日完成了工商变更登记及备案手续，并取得了呼和浩特市行政审批 和政务服务局颁发的《营业执照》，现将具体信息公告如下： 统一社会信用代码：91 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 金河生物科技股份有限公司 2025年半年度业绩预告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚假记载、误导性陈述或者重 大遗漏承担责任。 一、本期业绩预计情况 （一）业绩预告期间 本次业绩预告的会计期间为2025年1月1日至2025年6月30日。 （二）业绩预告情况：预计净利润为正值且属于下列情形之一： □扭亏为盈 √同向上升 □同向下降 证券代码：002688 证券简称：金河生物 公告编号:2025-063 二、与会计师事务所沟通情况 公司本次业绩预告未经注册会计师审计。 三、业绩变动原因说明 本报告期，公司兽用化学药品板块销售持续向好，主要产品金霉素内外销市场销量齐增，特别是海外市 场销量继续增长。公司六期工程项目投产后，产量增加，保障了国内外市场供货需求，创造了更多利 润。农产品加工板块由于主要原材料玉米价格进一步回落，对整体业绩提升亦做出较多贡献。 四、风险提示 （一）本次业绩预告数据为公司财务部门初步测算的结果，具体财务数据将在2025年半年度报告中详细 披露。敬请广大投资者谨慎决策，注意投资风险。 （二）公司指定信息披露媒体 ...

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, highlighting changes in control, major asset acquisitions, and performance forecasts for the first half of 2025. Group 1: Control Changes and Stock Suspension - Yangdian Technology is planning a change in control, leading to a stock suspension starting July 14, 2025, for up to 2 trading days [3] - Yuanli Co. is also planning to acquire control of Fujian Tongsheng New Materials Technology, resulting in a stock suspension starting July 14, 2025, for up to 10 trading days [5] - Kanghua Bio is planning a change in control, with stock suspension starting July 14, 2025, for up to 2 trading days [6] - Fuda Alloy is planning to acquire at least 51% of Guangda Electronics, which constitutes a major asset restructuring but will not change the actual controller [7] Group 2: Performance Forecasts - Limin Co. expects a net profit of 260 million to 280 million yuan for H1 2025, a year-on-year increase of 719.25% to 782.27% due to rising sales and prices [9] - Zijin Mining anticipates a net profit of approximately 23.2 billion yuan for H1 2025, a year-on-year increase of about 54% [10] - Chunqiu Electronics forecasts a net profit of 90 million to 110 million yuan for H1 2025, an increase of 236.05% to 310.72% [11] - Jinqilin expects a net profit of around 106 million yuan for H1 2025, a year-on-year increase of 222.36% [12] - Beihua Co. anticipates a net profit of 98 million to 111 million yuan for H1 2025, a year-on-year increase of 182.72% to 220.23% [14] - Guojin Securities expects a net profit of 1.092 billion to 1.137 billion yuan for H1 2025, a year-on-year increase of 140% to 150% [15] - Jiu Yuan Silver Sea forecasts a net profit of 26.49 million to 32.25 million yuan for H1 2025, a year-on-year increase of 130% to 180% [16] - Lankai Technology expects a net profit of 1.1 billion to 1.2 billion yuan for H1 2025, a year-on-year increase of 85.5% to 102.36% [17] - Changcheng Securities anticipates a net profit of 1.335 billion to 1.407 billion yuan for H1 2025, a year-on-year increase of 85% to 95% [18] - Weilan Lithium Core expects a net profit of 300 million to 360 million yuan for H1 2025, a year-on-year increase of 79.29% to 115.15% [19] - Yinlong Co. forecasts a net profit of 161 million to 181 million yuan for H1 2025, a year-on-year increase of 60% to 80% [21] - Aopumai expects a net profit of approximately 37 million yuan for H1 2025, a year-on-year increase of 53.28% [22] - Bailong Dongfang anticipates a net profit of 350 million to 410 million yuan for H1 2025, a year-on-year increase of 50.21% to 75.97% [23] - Shanghai Electric expects a net profit of 1.754 billion to 2.087 billion yuan for H1 2025, a year-on-year increase of 32.18% to 57.27% [24] - Huazhong Securities expects a net profit of 1.035 billion yuan for H1 2025, a year-on-year increase of 44.94% [25] - Bailong Chuangyuan anticipates a net profit of 171 million yuan for H1 2025, a year-on-year increase of 42.68% [26] - Chengyi Pharmaceutical expects a net profit of 107 million to 119 million yuan for H1 2025, a year-on-year increase of 40% to 55% [27] - Jinhai Biological anticipates a net profit of 127 million to 141 million yuan for H1 2025, a year-on-year increase of 40% to 55% [28] - Kanda New Materials expects a net profit of 50 million to 55 million yuan for H1 2025, turning from loss to profit [29] - China Shenhua expects a net profit of 23.6 billion to 25.6 billion yuan for H1 2025, a year-on-year decrease of 8.6% to 15.7% [30] - ST Songfa anticipates a net profit of 580 million to 700 million yuan for H1 2025, turning from loss to profit [31] - Chengxing Co. expects a net profit of 16 million to 23 million yuan for H1 2025, turning from loss to profit [33] - Ningbo Fubon anticipates a net profit of 8 million to 12 million yuan for H1 2025, turning from loss to profit [34] - ST Yundong expects a loss of 100 million to 150 million yuan for H1 2025, worsening from the previous year [35] - Kairuide expects a loss of 15 million to 22 million yuan for H1 2025, turning from profit to loss [36] Group 3: Shareholding Changes - Defu Technology's shareholders plan to reduce their holdings by up to 4.04% [38] - Jinzhen Co.'s shareholders plan to reduce their holdings by up to 3.04% [39] - Shikong Technology's shareholder plans to reduce their holdings by up to 3% [40] - Qilu Bank's shareholder plans to reduce their holdings by up to 1.1% [41] - Zhongci Electronics' shareholder plans to reduce their holdings by up to 1% [42] - Jiamei Packaging's shareholders plan to reduce their holdings by up to 1% [43] - Saike Xide's shareholder plans to reduce their holdings by up to 1% [44] - Gongda High-tech's general manager plans to reduce their holdings by up to 0.3424% [46] - Qingyuan Co.'s shareholder plans to reduce their holdings by up to 273,800 shares [47] Group 4: Major Contracts - Dashijiang expects to win a procurement project worth 122 million yuan [49] - Robotech signed significant daily operational contracts worth approximately 14.18 million USD [50]

Corporate Announcements - Yangdian Technology is planning a change in control, leading to a suspension of its stock from July 14, 2025, for up to 2 trading days [3] - Degute is planning to acquire 100% of Haowei Technology through a combination of share issuance and cash payment, with stock resuming trading on July 14, 2025 [4] - Yuanli Co. is planning to acquire control of Fujian Tongsheng New Materials Technology, resulting in a stock suspension starting July 14, 2025, for up to 10 trading days [5] - Kanghua Bio is also planning a change in control, with stock suspension from July 14, 2025, for up to 2 trading days [6] - Fuda Alloy is planning to acquire at least 51% of Guangda Electronics, which will constitute a major asset restructuring but will not change the actual controller [7] Performance Forecasts - Limin Co. expects a net profit of 260 million to 280 million yuan for the first half of 2025, a year-on-year increase of 719.25% to 782.27% [9] - Zijin Mining anticipates a net profit of approximately 23.2 billion yuan for the first half of 2025, a year-on-year increase of about 54% [10] - Chunqiu Electronics forecasts a net profit of 9 million to 11 million yuan, an increase of 236.05% to 310.72% year-on-year [12] - Jinqilin expects a net profit of approximately 106 million yuan, a year-on-year increase of 222.36% [13] - Beihua Co. anticipates a net profit of 98 million to 111 million yuan, a year-on-year increase of 182.72% to 220.23% [14] - Guojin Securities expects a net profit of 1.092 billion to 1.137 billion yuan, a year-on-year increase of 140% to 150% [15] - Jiuyuan Silver Sea forecasts a net profit of 26.49 million to 32.25 million yuan, a year-on-year increase of 130% to 180% [16] - Lankai Technology expects a net profit of 1.1 billion to 1.2 billion yuan, a year-on-year increase of 85.5% to 102.36% [17] - Changcheng Securities anticipates a net profit of 1.335 billion to 1.407 billion yuan, a year-on-year increase of 85% to 95% [18] - Weilan Lithium Core expects a net profit of 300 million to 360 million yuan, a year-on-year increase of 79.29% to 115.15% [19] - Yinlong Co. forecasts a net profit of 161 million to 181 million yuan, a year-on-year increase of 60% to 80% [20] - Aopumai expects a net profit of approximately 37 million yuan, a year-on-year increase of 53.28% [22] - Bailong Dongfang anticipates a net profit of 350 million to 410 million yuan, a year-on-year increase of 50.21% to 75.97% [23] - Shanghai Electric expects a net profit of 1.754 billion to 2.087 billion yuan, a year-on-year increase of 32.18% to 57.27% [24] - Huazheng Securities reports a net profit of 1.035 billion yuan, a year-on-year increase of 44.94% [25] - Bailong Chuangyuan expects a net profit of 171 million yuan, a year-on-year increase of 42.68% [26] - Chengyi Pharmaceutical anticipates a net profit of 107 million to 119 million yuan, a year-on-year increase of 40% to 55% [27] - Jinhai Biological expects a net profit of 127 million to 141 million yuan, a year-on-year increase of 40% to 55% [28] - Kangda New Materials forecasts a net profit of 50 million to 55 million yuan, turning from loss to profit [29] - China Shenhua expects a net profit of 23.6 billion to 25.6 billion yuan, a year-on-year decrease of 8.6% to 15.7% [30] - ST Songfa anticipates a net profit of 580 million to 700 million yuan, turning from loss to profit [31] - Chengxing Co. expects a net profit of 16 million to 23 million yuan, turning from loss to profit [32] - Bofubang anticipates a net profit of 8 million to 12 million yuan, turning from loss to profit [33] - ST Yundong expects a loss of 100 million to 150 million yuan, an increase in loss compared to the previous year [34] - Kerryde expects a loss of 15 million to 22 million yuan, turning from profit to loss [35] Shareholding Changes - Defu Technology's shareholders plan to reduce their holdings by up to 4.04% [37] - Jinzhen Co.'s shareholders plan to reduce their holdings by up to 3.04% [38] - Shikong Technology's shareholder plans to reduce their holdings by up to 3% [39] - Qilu Bank's shareholder plans to reduce their holdings by up to 1.1% [40] - Zhongci Electronics' shareholder plans to reduce their holdings by up to 1% [41] - Jiamei Packaging's shareholders plan to reduce their holdings by up to 1% [42] - Saike Xide's shareholder plans to reduce their holdings by up to 1% [43] - Gongda High-Tech's general manager plans to reduce their holdings by up to 0.3424% [44] - Qingyuan Co.'s shareholder plans to reduce their holdings by up to 273,800 shares [45] Major Contracts - Dash Intelligent has been pre-awarded a procurement project worth 122 million yuan [46] - Robotech has signed significant daily operational contracts amounting to approximately 1.418 million USD [48]

智通财经7月13日电，金河生物(002688.SZ)公告称，金河生物发布2025年半年度业绩预告，预计归属于 上市公司股东的净利润为1.27亿元-1.41亿元，比上年同期增长40%-55%。报告期内，兽用化学药品板块 销售持续向好，主要产品金霉素内外销市场销量齐增，尤其是海外市场销量继续增长；六期工程项目投 产后产量增加，保障了供货需求，创造了更多利润。农产品加工板块因主要原材料玉米价格回落，对整 体业绩提升亦有贡献。 金河生物：上半年净利预增40%-55% ...

证券代码：002688 证券简称：金河生物 公告编号:2025-063 金河生物科技股份有限公司 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、本期业绩预计情况 （一）业绩预告期间 本次业绩预告的会计期间为 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况：预计净利润为正值且属于下列情形之一： ?扭亏为盈 ?同向上升 ?同向下降 项 目 本报告期 上年同期 归属于上市公司股东 盈利：12,742.88 万元-14,108.19 万元 盈利：9,102.06 万元 的净利润 比上年同期增长 40%-55% 扣除非经常性损益后 盈利：11,782.73 万元–13,148.04 万元 归属于上市公司股东 盈利：8,494.87 万元 比上年同期增长：38.70%-54.78% 的净利润 基本每股收益 盈利：0.1651 元/股-0.1828 元/股 盈利：0.1166 元/股 二、与会计师事务所沟通情况 公司本次业绩预告未经注册会计师审计。 三、业绩变动原因说明 本报告期，公司兽用化学药品板块销售持续向好，主要 ...

证券代码：002688 证券简称：金河生物 公告编号:2025-063 金河生物科技股份有限公司 2025 年半年度业绩预告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 | 项 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司股东 | 盈利：12,742.88 | 万元-14,108.19 万元 | 盈利：9,102.06 | 万元 | | 的净利润 | 比上年同期增长 | 40%-55% | | | | 扣除非经常性损益后 归属于上市公司股东 | 盈利：11,782.73 | 万元–13,148.04 万元 | 盈利：8,494.87 | 万元 | | | 比上年同期增长：38.70%-54.78% | | | | | 的净利润 | | | | | | 基本每股收益 | 盈利：0.1651 | 元/股-0.1828 元/股 | 盈利：0.1166 | 元/股 | 二、与会计师事务所沟通情况 公司本次业绩预告未经注册会计师审计。 三、业绩变动原因说明 本报告期，公司兽 ...

Group 1: Project and Investment Updates - The company has not arranged for the construction of the erythritol project and has no related information to provide at this time [1] - The company has completed fundraising but has no specific plans for the erythritol project, nor a timeline for construction [1] - The company is focusing on existing projects and has no further restructuring plans [2] Group 2: Market and Trade Impact - The trade war has not affected the company's export products, and export volumes remain stable [1] - The company has implemented price increases in the U.S. market to cover tariff costs [1] - The company maintains a stable market share globally, despite fluctuations in international trade [1] Group 3: Product Performance and Sales - The company's chemical drug product, Jinmeisu, has maintained a high reputation and stable supply-demand relationship in the market [2] - The main vaccine product, Blue Ear Inactivated Vaccine, continues to hold the number one market share [2] - The company’s new production capacity for chemical drugs is currently at 100% utilization [2] Group 4: Future Development Strategies - The company aims to enhance product quality, innovation capabilities, and market share to ensure steady profit growth [2] - The company is actively pursuing strategic development goals and aims to achieve a market value of 20 billion [3] - The company is exploring new avenues in the animal health sector while focusing on existing product development [2] Group 5: Financial and Operational Insights - The company’s logistics costs for the first half of 2025 are still being compiled, with details to be disclosed in the upcoming half-year report [5] - The company has invested 158 million in a wastewater treatment project to enhance its capabilities and profitability [4] - The company is closely monitoring the impact of corn price fluctuations on product costs and adjusting procurement strategies accordingly [4]

Market Overview - The Shanghai Composite Index fell by 0.13% on July 9, with 17 out of the 28 sectors rising, led by Media and Agriculture, Forestry, Animal Husbandry, and Fishery, which increased by 1.35% and 0.65% respectively [2] - The sectors with the largest declines were Non-ferrous Metals and Basic Chemicals, which dropped by 2.26% and 0.85% respectively [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 38.536 billion yuan, with only three sectors experiencing net inflows: Media (1.055 billion yuan), Retail (864 million yuan), and Construction Decoration (40.34 million yuan) [2] - The Electronic sector saw the largest net outflow, amounting to 7.789 billion yuan, followed by Non-ferrous Metals with 5.412 billion yuan [2] Agriculture, Forestry, Animal Husbandry, and Fishery Sector - The Agriculture, Forestry, Animal Husbandry, and Fishery sector rose by 0.65% despite a net capital outflow of 437 million yuan [3] - Out of 103 stocks in this sector, 40 stocks increased, with one hitting the daily limit, while 55 stocks declined [3] - The top three stocks with net inflows were Xinwufeng (31.4665 million yuan), Haida Group (28.3706 million yuan), and Juxing Agriculture (21.9941 million yuan) [3][4] Top Gainers and Losers in Agriculture, Forestry, Animal Husbandry, and Fishery - **Top Gainers**: - Xinwufeng: +0.65%, 4.20% turnover, 31.4665 million yuan inflow [4] - Juxing Agriculture: +0.76%, 4.49% turnover, 21.9941 million yuan inflow [4] - **Top Losers**: - Muyuan Foods: -3.27%, 1.81% turnover, 71.5922 million yuan outflow [5] - Guolian Aquatic Products: -1.76%, 8.74% turnover, 45.2607 million yuan outflow [5]

本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 证券代码：002688 证券简称：金河生物 公告编号:2025-062 金河生物科技股份有限公司 关于参加内蒙古辖区上市公司2025年投资者 网上集体接待日活动的公告 2025年7月9日 1 为进一步加强与投资者的互动交流，金河生物科技股份有限公司（以下简 称"公司"）将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全景网络 有限公司联合举办的"2025年内蒙古辖区上市公司投资者集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (http://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演APP参 与本次互动交流，活动时间为2025年7月11日(周五)16:00-18:00。届时公司高 管将在线就公司2024年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎 广大投资者踊跃参与！ 特此公告。 金河生物科技股份有限公司 董 事 会 ...